January 20, 2022 10:47 pm | Updated 10:47 pm IST - Hyderabad
Generic drugmaker Zydus has received the final approval from the U.S. FDA to market anticonvulsant drug Vigabatrin Tablets 500 mg. The approved product, whose reference listed drug is Sabril Tablets, will be manufactured at the Group’s formulation manufacturing facility in Ahmedabad, Cadila Healthcare said on Thursday. Vigabatrin decreases the number of seizures in adults and children who have not been able to control their seizures with other treatment, the company said.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.
